Meeting
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Association of an RNA signature (RS) with emergence of ICOS hi CD4 T cells and efficacy outcomes for the ICOS agonist vopratelimab (vopra) and nivolumab (nivo) in patients (pts) on the ICONIC trial.
Authors
Timothy A Yap
The University of Texas MD Anderson Cancer Center, Houston, TX
Timothy A Yap, Justin F. Gainor, Howard A. Burris, Shivaani Kummar, Russell Kent Pachynski, Margaret K. Callahan, Patricia LoRusso, Scott S. Tykodi, Geoffrey Thomas Gibney, Gerald Steven Falchook, Osama E. Rahma, Tanguy Y. Seiwert, Kyriakos P. Papadopoulos, James Walter Mier, Yasmin Hashambhoy-Ramsay, Daniel Felitsky, David Y. Lee, Lara McGrath, Christopher Harvey, Ellen Hooper
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Biomarkers and Inflammatory Signatures
Clinical Trial Registration Number
NCT02904226
Citation
J Clin Oncol 38, 2020 (suppl 5; abstr 14)
Abstract #
14
Poster Bd #
B8
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase 2 study of PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected subjects with metastatic NSCLC after one prior platinum-containing regimen (SELECT).
First Author: Oleh Kobziev
Poster
2024 ASCO Annual Meeting
Spatially resolved multi-region proteomics for prediction of clinical outcome in deficient mismatch repair metastatic colorectal cancer treated with PD-1 blockade.
First Author: Bahar Saberzadeh Ardestani
First Author: Cailin Joyce
Poster
2017 ASCO Annual Meeting
Effect of PD1/PD-L1 checkpoint blockade on efficacy of anti-GD2 antibody ch14.18/CHO in neuroblastoma.
First Author: Holger N. Lode